Setmelanotide
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway
Rhythm · Phase 3 · Completed · Enrollment 19
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Run-in Period: Setmelanotide 2 mg QD | 0 participants | 0 participants | 0 participants | n/r | 0 |
| Run-in Period: Setmelanotide 2.5 mg QD | 0 participants | 0 participants | 0 participants | n/r | 0 |
| Run-in Period: Setmelanotide 3 mg QD | 0 participants | 0 participants | 0 participants | n/r | 0 |
| DB Period: Setmelanotide 20 mg QW | 0 participants | 0 participants | 0 participants | n/r | 0 |
| DB Period: Setmelanotide 25 mg QW | 1 participants | 0 participants | 0 participants | n/r | 0 |
| DB Period: Setmelanotide 3 mg QD | 3 participants | 2 participants | 2 participants | n/r | 0 |
| DB Period: Setmelanotide 30 mg QW | 0 participants | 0 participants | 0 participants | n/r | 0 |
| OL Period: Setmelanotide 20 mg QW | 0 participants | 0 participants | 0 participants | n/r | 0 |
| OL Period: Setmelanotide 25 mg QW | 1 participants | 0 participants | 0 participants | n/r | 0 |
| OL Period: Setmelanotide 30 mg QW | 0 participants | 1 participants | 2 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.